An intricate rewiring of cancer metabolism via alternative splicing

Temaj G., Chichiarelli S., Saha S., Telkoparan-Akillilar P., Nuhii N., Hadziselimovic R., ...Daha Fazla

Biochemical Pharmacology, cilt.217, 2023 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 217
  • Basım Tarihi: 2023
  • Doi Numarası: 10.1016/j.bcp.2023.115848
  • Dergi Adı: Biochemical Pharmacology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, Biotechnology Research Abstracts, CAB Abstracts, Chemical Abstracts Core, Chimica, EMBASE, Veterinary Science Database
  • Anahtar Kelimeler: Alternative splicing, Cancer, Metabolism
  • Gazi Üniversitesi Adresli: Hayır

Özet

All human genes undergo alternative splicing leading to the diversity of the proteins. However, in some cases, abnormal regulation of alternative splicing can result in diseases that trigger defects in metabolism, reduced apoptosis, increased proliferation, and progression in almost all tumor types. Metabolic dysregulations and immune dysfunctions are crucial factors in cancer. In this respect, alternative splicing in tumors could be a potential target for therapeutic cancer strategies. Dysregulation of alternative splicing during mRNA maturation promotes carcinogenesis and drug resistance in many cancer types. Alternative splicing (changing the target mRNA 3′UTR binding site) can result in a protein with altered drug affinity, ultimately leading to drug resistance. Here, we will highlight the function of various alternative splicing factors, how it regulates the reprogramming of cancer cell metabolism, and their contribution to tumor initiation and proliferation. Also, we will discuss emerging therapeutics for treating tumors via abnormal alternative splicing. Finally, we will discuss the challenges associated with these therapeutic strategies for clinical applications.